Tobacco harm reduction is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. Biomarkers specific for the exposure to tobacco and smoke are key endpoints for evaluating new emerging nicotine products with a potentially reduced risk.
Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review
Regulatory Toxicology and Pharmacology, Volume 94, doi: 10.1016/j.yrtph.2018.02.002
Analysis of Urinary Eicosanoids by LC-MS/MS Reveals Alterations in the Metabolic Profile after Smoking Cessation
Chemical Research in Toxicology, Volume 31, doi: 10.1021/acs.chemrestox
Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform
Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products